Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1841Neoplasms 1230Colorectal Neoplasms 1046Carcinoma, Non-Small-Cell Lung 996Stomach Neoplasms 787Carcinoma, Hepatocellular 780Lung Neoplasms 756Prostatic Neoplasms 682Pancreatic Neoplasms 567Rectal Neoplasms 444Colonic Neoplasms 401Neoplasm Metastasis 400Ovarian Neoplasms 399Uterine Cervical Neoplasms 395Recurrence 380Leukemia, Myeloid, Acute 367Esophageal Neoplasms 352Multiple Myeloma 340Lymphoma 330Head and Neck Neoplasms 326Melanoma 306Precursor Cell Lymphoblastic Leukemia-Lymphoma 288Brain Neoplasms 263Urinary Bladder Neoplasms 249Nasopharyngeal Carcinoma 221Liver Neoplasms 221Leukemia 217Lymphoma, Large B-Cell, Diffuse 213Polycystic Ovary Syndrome 206Squamous Cell Carcinoma of Head and Neck 200

Interventions

apatinib 1PE regimen 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Progression Free Survival × Clear all
NCT03100955 2017-04-04

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Qingdao University

Phase 3 Unknown
120 enrolled

Progression Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡